Bernstein analyst Vincent Chen started coverage on PTC Therapeutics (PTCT) with an Outperform rating and a $48 price target, given his positive view on the commercial potential of risdiplam in SMA. The analyst believes that there will still be a substantial market opportunity for non-gene therapy drugs after approval, and thinks risdiplam's oral dosing will be a substantial advantage over Biogen (BIIB) Spinraza's intrathecal administration. If risdiplam is safe and comparably efficacious to Spinraza, Chen forecasts potential for $2.5B in revenues by 2030.